Literature DB >> 11025248

Diabetes mellitus and cancer.

.   

Abstract

Although an association between diabetes and cancer was found over 100 years ago, the issue underwent different interpretations over the subsequent decades, and only modern, prospective, epidemiological cohort and case-control studies conducted in several countries have provided reliable evidence of an increased cancer risk in diabetic patients, mainly in those with type 2 diabetes. This risk varies according to the tumor site: it is the greatest for primary liver cancer, moderately elevated for pancreatic cancer, and relatively low for colorectal, endometrial, breast, and renal cancers. The cause of the association is not clear and remains the subject of different hypotheses. The most frequently cited reason is the potential effect of insulin. Found in high concentrations, due to insulin resistance in most patients with type 2 diabetes, this hormone is believed to express a mitogenic effect. This hypothesis needs to be confirmed in appropriately programmed prospective studies, but it may already be helpful in choosing an adequate treatment for type 2 diabetes to achieve optimal metabolic control with a simultaneous reduction in hyperinsulinemia, such as diet, physical exercise, metformin, and acarbose.

Entities:  

Year:  2000        PMID: 11025248     DOI: 10.1016/s0953-6205(00)00106-0

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  19 in total

Review 1.  The complexities of obesity and diabetes with the development and progression of pancreatic cancer.

Authors:  Bin Bao; Zhiwei Wang; Yiwei Li; Dejuan Kong; Shadan Ali; Sanjeev Banerjee; Aamir Ahmad; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-12-01

Review 2.  Leptin revisited: its mechanism of action and potential for treating diabetes.

Authors:  Roberto Coppari; Christian Bjørbæk
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

3.  Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas.

Authors:  Xiao-Ping Li; Zhen Chen; Zhi-Qiang Meng; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

4.  Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas.

Authors:  M Toaiari; M V Davì; L Dalle Carbonare; L Boninsegna; C Castellani; M Falconi; G Francia
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

5.  Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.

Authors:  Bethany P Cummings; Ahmed Bettaieb; James L Graham; Kimber Stanhope; Fawaz G Haj; Peter J Havel
Journal:  J Endocrinol       Date:  2014-03-13       Impact factor: 4.286

6.  Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities.

Authors:  C Y Hsu; R S Sulake; P-K Huang; H-Y Shih; H-W Sie; Y-K Lai; C Chen; C F Weng
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

Review 7.  Plasmalemmal vacuolar H+-ATPases in angiogenesis, diabetes and cancer.

Authors:  Souad R Sennoune; Raul Martinez-Zaguilan
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

8.  Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.

Authors:  Grace Sun; Sangeeta R Kashyap
Journal:  J Nutr Metab       Date:  2011-06-01

9.  Diabetes and risk of renal cell carcinoma.

Authors:  Samy L Habib; Thomas J Prihoda; Maria Luna; Sherry A Werner
Journal:  J Cancer       Date:  2011-12-24       Impact factor: 4.207

10.  Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes.

Authors:  D Basso; C Millino; E Greco; C Romualdi; P Fogar; A Valerio; M Bellin; C-F Zambon; F Navaglia; N Dussini; A Avogaro; S Pedrazzoli; G Lanfranchi; M Plebani
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.